fbpx

Heart transplantation

Updated : September 2, 2022





Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

 

mycophenolate 

Note: The concurrent administration of this medication alongside cyclosporine and corticosteroids is recommended for the prevention of organ rejection in individuals who have undergone allogeneic cardiac transplants
MMF: Administration of 1.5 grams of the medication orally or intravenously twice a day, with a minimum infusion duration of 2 hours



 

mycophenolate 

only CellCept
Note: Recommended for the prevention of organ rejection in pediatric patients aged three months or older who have undergone allogeneic heart transplantation when used in conjunction with other immunosuppressive medications
Suspension: The recommended starting dose of suspension is 600 mg/ m² taken twice daily by oral route
If the patient tolerates this dose, The maintenance dose of 900 mg/ m² can be increased and administered twice daily, with a maximum daily limit of 3 grams
Capsules: For patients with a body surface area (BSA) between 1.25 and less than 1.5 m², the initial recommended dose is a capsule 750 mg twice daily by oral route
The maintenance dose may be increased but should not exceed 3 grams/day
Capsules or tablets: Patients with a BSA of 1.5 m², or greater should start with a 1-gram tablet/capsule twice daily by oral route
The maintenance dose may be increased but should not exceed 3 grams/day



 

Media Gallary

References

Heart transplantation

Updated : September 2, 2022




mycophenolate 

Note: The concurrent administration of this medication alongside cyclosporine and corticosteroids is recommended for the prevention of organ rejection in individuals who have undergone allogeneic cardiac transplants
MMF: Administration of 1.5 grams of the medication orally or intravenously twice a day, with a minimum infusion duration of 2 hours



mycophenolate 

only CellCept
Note: Recommended for the prevention of organ rejection in pediatric patients aged three months or older who have undergone allogeneic heart transplantation when used in conjunction with other immunosuppressive medications
Suspension: The recommended starting dose of suspension is 600 mg/ m² taken twice daily by oral route
If the patient tolerates this dose, The maintenance dose of 900 mg/ m² can be increased and administered twice daily, with a maximum daily limit of 3 grams
Capsules: For patients with a body surface area (BSA) between 1.25 and less than 1.5 m², the initial recommended dose is a capsule 750 mg twice daily by oral route
The maintenance dose may be increased but should not exceed 3 grams/day
Capsules or tablets: Patients with a BSA of 1.5 m², or greater should start with a 1-gram tablet/capsule twice daily by oral route
The maintenance dose may be increased but should not exceed 3 grams/day